Math Proves HME’s Value
Upcoming VGM study to be released at Medtrade demonstrates HME’s ROI.
- By David Kopf
- Oct 06, 2011
A new study from the VGM Group that will be unveiled at Medtrade 2011 this month mathematically proves a positive return on investment in DME , the industry group reports, adding that the findings might help CMS “put two and two together. “
The report, The Case for Medicare Investment in DME, demonstrates that for every dollar Medicare pays to provide supplemental oxygen therapy, it avoids spending between $5.79 and $6.07 for treatment of COPD-related complications, according to VGM.
The full report will be released sometime during the week of Medtrade 2011, slated to be held from Oct. 25 to 27 at the Georgia World Congress Center, in Atlanta.
About the Author
David Kopf is the Editor of HME Business.